Dabigatran Etexilate Mesylate Powder CAS 872728-81-9 Raw Material

CAS: 872728-81-9

MF: C35H45N7O8S

MW: 723.85

EINECS: 828-727-6

Specification​: 99% min Dabigatran Etexilate Mesylate

Sample: Dabigatran Etexilate Mesylate Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Portal:https://henrikang.en.made-in-china.com/

Dabigatran Etexilate Mesylate Powder Usage and Synthesis.

Dabigatran Etexilate Mesylate Powder is a clinical direct thrombin inhibitor and a new type of oral anticoagulant. The mechanism of action of Dabigatran Etexilate Mesylate CAS 872728-81-9 is to inhibit the formation of thrombin by reversibly competing for fibrin-specific binding sites that bind thrombin.
Dabigatran Etexilate Mesylate Raw Material is a precursor drug of Dabigatran that is metabolized in the body and converted into an active dabigatran.

Uses and functions of Dabigatran Etexilate Mesylate Powder.

Dabigatran Etexilate Mesylate Powder is a new oral anticoagulant drug approved by the US Food and Drug Administration after warfarin. It is a non-peptide prothrombin inhibitor that exerts its anticoagulant effect by specifically and selectively blocking the activity of prothrombin (free or bound). It is an important milestone in the field of anticoagulant therapy and potentially lethal thromboprophylaxis, as it can be taken orally, is potent, requires no special dosing monitoring and has few drug interactions.

After oral absorption through the gastrointestinal tract, dabigatran is converted in vivo into dabigatran, which has direct anticoagulant activity and blocks the final step of the coagulation waterfall network and thrombosis by binding to the fibrin-specific binding site of thrombin and preventing the cleavage of fibrinogen into fibrin. Dabigatran also dissociates from the fibrin-mono-thrombin conjugate and exerts a reversible anticoagulant effect.

Dabigatran Etexilate Mesylate Powder is a hematologic API; an anticoagulant; used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation; dabigatran is a novel synthetic direct thrombin inhibitor, a precursor to dabigatran, and a non-peptide thrombin inhibitor.

Pharmacological Effects of Dabigatran Etexilate Mesylate Powder.

Dabigatran Etexilate Mesylate Powder is a precursor drug to dabigatran and is metabolised in vivo to active dabigatran. Compared to warfarin, dabigatranate mesylate eliminates the need for frequent monitoring of coagulation and dose adjustments during treatment, Dabigatran Etexilate Mesylate has fewer drug-drug interactions and is not affected by food intake, thus improving patient compliance.

Dabigatranate significantly reduced the risk of stroke and embolic disease (including haemorrhagic stroke), significantly reduced the incidence of bleeding (including fatal bleeding and intracranial bleeding) and significantly reduced vascular mortality. The results of the study also showed that dabigatranate provided effective and stable anticoagulation without the need for routine monitoring of coagulation and adjustment of dosing.